A comparative assessment of neutropenia events, healthcare resource use, and costs among patients treated with long-acting granulocyte-colony stimulating factor in Germany

被引：0
|
作者：
Link, H. [1 ]
Thompson, S. F. [2 ]
Tian, M. [3 ]
Meise, D. [4 ]
Haas, J. S. [4 ]
Maas, C. [4 ]
Dimitrov, S. [5 ]
机构：
[1] Private Practice Haematol & Oncol, Haematol & Oncol, Kaiserslautern, Germany
[2] TEVA Pharmaceut, Oncol, Parsippany, NJ USA
[3] TEVA Pharmaceut, Oncol, W Chester, PA USA
[4] Xcenda GmbH, Oncol, Hannover, Germany
[5] TEVA Pharmaceut, Oncol, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1678
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1706P
引用
收藏
页码：S1189 / S1189
页数：1
相关论文
共 48 条
  • [21] Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany
    Peter Greven
    Vanja Sikirica
    Yaozhu J. Chen
    Tammy G. Curtice
    Charles Makin
    The European Journal of Health Economics, 2017, 18 : 893 - 904
  • [22] Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany
    Greven, Peter
    Sikirica, Vanja
    Chen, Yaozhu J.
    Curtice, Tammy G.
    Makin, Charles
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2017, 18 (07): : 893 - 904
  • [23] EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
    Aapro, M. S.
    Cameron, D. A.
    Pettengell, R.
    Bohlius, J.
    Crawford, J.
    Ellis, M.
    Kearney, N.
    Lyman, G. H.
    Tjan-Heijnen, V. C.
    Walewski, J.
    Weber, D. C.
    Zielinski, C.
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) : 2433 - 2453
  • [24] Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer
    Griffiths, Robert I.
    Barron, Richard L.
    Gleeson, Michelle L.
    Danese, Mark D.
    O'Hagan, Anthony
    Chia, Victoria M.
    Legg, Jason C.
    Lyman, Gary H.
    PHARMACOECONOMICS, 2012, 30 (02) : 103 - 118
  • [25] Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer
    Griffiths R.I.
    Barron R.L.
    Gleeson M.L.
    Danese M.D.
    Ohagan A.
    Chia V.M.
    Legg J.C.
    Lyman G.H.
    PharmacoEconomics, 2012, 30 (2) : 103 - 118
  • [26] Multi-cycle prophylaxis of long-acting granulocyte colony-stimulating factor in tumor patients at risk of neutropenia due to myelosuppressive chemotherapy: A retrospective real-world study
    Song, Q.
    Li, B.
    Shen, Z.
    Zhang, Y.
    Wu, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1611 - S1611
  • [27] EARLY INITIATION OF LONG-ACTING INJECTABLE ANTIPSYCHOTIC TREATMENT IS ASSOCIATED WITH LOWER HEALTHCARE RESOURCE USE AND COSTS IN PATIENTS WITH SCHIZOPHRENIA
    Munday, J. S.
    Broder, M. S.
    Chang, E.
    Hartry, A.
    Yan, T.
    Greene, M.
    VALUE IN HEALTH, 2018, 21 : S5 - S5
  • [28] Febrile Neutropenia Risk Assessment and Granulocyte-Colony Stimulating Factor Support in Patients with Diffuse Large B Cell Lymphoma Receiving R-CHOP Regimens
    Salar, Antonio
    Haioun, Corinne
    Rossi, Francesca Gaia
    Duehrsen, Ulrich
    Pettengell, Ruth
    Johnsen, Hans Erik
    Jaeger, Ulrich
    Verhoef, Gregor
    Schwenkglenks, Matthias
    Principe, Fernando
    Bacon, Pamela
    Bendall, Kate
    Lugtenburg, P. J.
    BLOOD, 2009, 114 (22) : 49 - 50
  • [29] Effect of Primary Prophylactic Granulocyte-Colony Stimulating Factor Use on Incidence of Neutropenia Hospitalizations for Elderly Early-stage Breast Cancer Patients Receiving Chemotherapy
    Rajan, Suja S.
    Lyman, Gary H.
    Stearns, Sally C.
    Carpenter, William R.
    MEDICAL CARE, 2011, 49 (07) : 649 - 657
  • [30] Reduction of Granulocyte-Colony Stimulating Factor Requirement in the Course of Long-Term Treatment for More Than 5 Years in Congenital Neutropenia Patients Harbouring ELANE Mutations
    Zeidler, Cornelia
    Nickel, Anna
    Grote, Ulrike A. H.
    Mellor-Heineke, Sabine
    Welte, Karl
    BLOOD, 2014, 124 (21)
12345